Email this article Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain
- Authors: Zolotovskaya IA1, Davydkin IL1
-
Affiliations:
- Issue: Vol 87, No 12 (2015)
- Pages: 18-25
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31863
- ID: 31863
Cite item
Full Text
Abstract
Aim. To evaluate the safety of etoricoxib in patients with acute nonspecific back pain associated with the high risk of cardiovascular events (CVE) in clinical practice. Subjects and methods. The open prospective follow-up by a simple randomization method included 80 patients, including 49 women and 31 men (mean 60.8±4.7 years). The patients were randomized into 4 groups of 20 persons each: 1) etoricoxib 90 mg/day; 2) nimesulide 100 mg/day; 3) diclofenac 100 mg/day; 4) meloxicam 15 mg/day. The investigation lasted 90±4.5 days. The interim evaluation criteria (study points) were pain changes using a visual analog scale (VAS); blood pressure (BP) changes; diurnal BP rhythm; and changes in coagulation hemostatic parameters and blood biochemical markers. The primary evaluation criteria (study endpoints) were the incidence of CVE in the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Results. The patients with acute back pain were shown to have a high incidence of comorbidities during outpatient care. The administration of NSAIDs resulted in a significant reduction in the magnitude and intensity of pain syndrome according to VAS in all the groups just on day 3 of therapy with a more marked analgesia in patients receiving etoricoxib and diclofenac. All the groups exhibited an increase in average daily systolic and diastolic BP with the most favorable profile in Group 1 patients. The intake of etoricoxib and other NSAIDs provided no evidence for changes in hemostatic parameters and biochemical markers during 10 weeks. The safety of etoricoxib was comparable with that of NSAIDs in its effect on the plasma hemostatic system. Conclusion. Unlike nimesulide, diclofenac, and meloxicam, etoricoxib was characterized by a rapid steady-state analgesic effect with a less pronounced action on diurnal BP rhythm. Within 3 months after treatment, no acute CVE was recorded in the patients taking etoricoxib.
References
- Герасимова О.Н., Парфенов В.А. Ведение пациентов с болью в спине в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2010;2:4.
- Каратеев А.Е., Алексеева Л.И., Аникин С.Г. Комбинация напроксена и эзомепразола: обезболивающая терапия при соблюдении баланса кардиоваскулярного и желудочно-кишечного риска. Современная ревматология. 2013;7:1. doi: 10.14412/1996-7012-2013-2374
- Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
- Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J. 2005;330(11):1366-1372.
- Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978-984.
- Подчуфарова Е.В., Яхно Н.Н. Боль в спине. М.; 2010.
- Неврология. Национальное руководство. Краткое издание. Под ред. Гусева Е.И., Коновалова А.Н., Гехт А.Б. М.: ГЭОТАР-Медиа; 2014.
- Белоусов Ю.Б., Кукес В.Г., Лепахин В.К., Петров В.И. Клиническая фармакология: национальное руководство. М.: ГЭОТАР-Медиа; 2014.
- Curtis SP, Ng J, Yu Q et al. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther. 2004;26:70-83.
- Повереннова И.Е., Золотовская И.А. Цереброваскулярные риски и прогнозирование развития осложнений у пациентов с болью в спине на фоне приема нестероидных противовоспалительных препаратов. Терапевтический архив. 2015;87(5): 53-58.
- Dalmora SL, Sangoi MS, Wrasse M, Bernardi RM, Ferretto RM, Fronza M. Evaluation of the changes in hemostatic parameters induced by etoricoxib in rat model. Blood Coagul Fibrinolysis. 2008;19(3):254-257. doi: 10.1097/mbc.0b013e3282f2b5ea.
Supplementary files
